https://www.selleckchem.com/products/bi-d1870.html
Response was independent of the PD-1 inhibitor usedand also independent of the presence of distant metastases vs. locally advanced disease. Two predictive factors were found Patients with primaries located on the leg had a poorer therapy outcomeand patients with high lactate dehydrogenase serum levels at baseline. Treatment was overall tolerated well, with less than 10% of patients discontinuing therapy due to toxicity. PD-1 inhibitors fulfill the need for an efficient systemic therapy for advanced cSCC and should be the new standard o
Like
Comment
Share
